Dr Jeremy Steele trained at St George’s Hospital Medical School, University of London. After a period of training in acute general medical specialities and intensive care medicine, he moved to the Royal Marsden Hospital to train in cancer medicine. There he undertook research into lung cancer, brain tumours and children’s leukaemia. He was awarded the degree of Doctor of Medicine for his thesis on cancer biology. He completed his oncology training at St Bartholomew’s Hospital (Barts) and the Royal London Hospital in London’s East End. In 1999 he was visiting fellow in the thoracic oncology centre of Harvard Medical School, Boston.
East London is the centre of the epidemic of malignant mesothelioma in London, and it was here that he led one of the first effective clinical trials of mesothelioma treatment. In 2002 he was appointed as consultant medical oncologist at Barts with special responsibility for lung cancer and mesothelioma.
Jeremy is well known in the UK as a specialist in lung cancer treatment and is internationally recognised as an expert in malignant mesothelioma diagnosis and treatment. Jeremy is secretary of the International Mesothelioma Group (iMig), based in Chicago, and is chairman of the advisory board of the Mesothelioma UK Charitable Trust. Jeremy has a longstanding commitment to patient advocacy and has successfully lobbied the UK Government on the provision of new cancer treatments.